Focused On-demand Library for Pleckstrin homology domain-containing family F member 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96S99

UPID:

PKHF1_HUMAN

Alternative names:

Lysosome-associated apoptosis-inducing protein containing PH and FYVE domains; PH and FYVE domain-containing protein 1; Phafin-1; Zinc finger FYVE domain-containing protein 15

Alternative UPACC:

Q96S99; Q96K11; Q9BUB9

Background:

Pleckstrin homology domain-containing family F member 1, also known as Phafin-1, plays a crucial role in apoptosis through the lysosomal-mitochondrial pathway. It facilitates the translocation to the lysosome, initiating lysosomal membrane permeabilization (LMP) and releasing CTSD and CTSL into the cytoplasm. This process triggers caspase-independent apoptosis by altering mitochondrial membrane permeabilization (MMP), leading to the release of PDCD8.

Therapeutic significance:

Understanding the role of Pleckstrin homology domain-containing family F member 1 could open doors to potential therapeutic strategies.